Treats unresectable or metastatic melanoma with BRAF V600E or V600K mutations. Sold as Mekinist. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 15, 2026, FDA lists 3 applications for Trametinib Dimethyl Sulfoxide (sold as Mekinist), first approved May 29, 2013, with 13 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Mekinist | Part D | $302M | +46% | 3,588 |
| Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade GliomasBRAF V600 Mutation, Low-grade Glioma · University of California, San Francisco | Phase 2 | Recruiting | Aug 7, 2025 |
| Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentClinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma · National Cancer Institute (NCI) | Phase 1 / Phase 2 | Active, not recruiting | Sep 22, 2020 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)Advanced Lymphoma, Advanced Malignant Solid Neoplasm · National Cancer Institute (NCI) | Phase 2 | Active, not recruiting | Jun 19, 2020 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)Advanced Lymphoma, Advanced Malignant Solid Neoplasm · National Cancer Institute (NCI) | Phase 2 | Active, not recruiting | Jun 19, 2020 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)Advanced Lymphoma, Advanced Malignant Solid Neoplasm · National Cancer Institute (NCI) | Phase 2 | Active, not recruiting | Jun 19, 2020 |
| Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)Advanced Lymphoma, Advanced Malignant Solid Neoplasm · National Cancer Institute (NCI) | Phase 2 | Active, not recruiting | Jun 19, 2020 |
| A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF AberrationLow Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration · Pediatric Brain Tumor Consortium | Phase 1 / Phase 2 | Active, not recruiting | Dec 17, 2019 |
| Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaAnaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified · National Cancer Institute (NCI) | Phase 2 | Active, not recruiting | Apr 18, 2019 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Novartis
Hikma